ESC/EACTS Guidelines for the management of valvular heart disease, Eur Heart J, vol.38, issue.36, pp.2739-91, 2017. ,
Transcatheter Aortic Valve Replacement in ,
One-Year Results from the LRT Trial, J AmColl Cardiol Intv, 2019. ,
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study, Lancet Lond Engl, vol.389, pp.2383-92, 2017. ,
Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke, Eur Heart J, vol.38, issue.16, pp.1207-1224, 2017. ,
A meta-analysis of reduced leaflet motion for surgical and transcatheter aortic valves: Relationship to cerebrovascular events and valve degeneration, Cardiovasc Revascularization Med Mol Interv, pp.868-73, 2018. ,
Medium-Term Follow-Up of Early Leaflet Thrombosis After Transcatheter Aortic Valve Replacement, J AmColl Cardiol Intv, vol.11, issue.12, pp.1164-71, 2018. ,
Treatment and clinical outcomes of transcatheter heart valve thrombosis, Circ Cardiovasc Interv, vol.8, issue.4, 2015. ,
Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes, J AmColl Cardiol Intv, vol.10, issue.7, pp.686-97, 2017. ,
Clinical or Symptomatic Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Insights from the U.S. FDA MAUDE Database. Struct Heart, vol.0, pp.1-9, 2017. ,
,
,
, Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: A retrospective single-center registry analysis, Cardiol J, vol.24, issue.6, pp.649-59, 2017.
Subclinical leaflet thrombosis following transcatheter aortic valve replacement, J Intervent Cardiol, vol.31, issue.5, pp.640-647, 2018. ,
Leaflet Thrombosis after TAVI, Eur Heart J, vol.38, issue.36, pp.2702-2705, 2017. ,
Bioprosthetic Valve Thrombosis, J Am Coll Cardiol ,
URL : https://hal.archives-ouvertes.fr/hal-01533431
Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes, Eur Heart J Cardiovasc Imaging, 2017. ,
,
, Bioprosthetic Aortic Valves, N Engl J Med, vol.373, issue.21, pp.2015-2039, 201519.
Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of ,
, Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of
, ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, vol.38, issue.45, pp.3382-90, 2017.
, Thromboembolic and Bleeding Complications in Transcatheter Aortic Valve Implantation: Insights on Mechanisms, Prophylaxis and Therapy
, J Clin Med, vol.8, issue.2, 2019.
Valve thrombosis following transcatheter aortic valve replacement: significance of blood stasis on the leaflets. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg, vol.51, pp.927-962, 2017. ,
Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves, Eur Heart J, vol.38, issue.28, pp.2201-2208, 2017. ,
Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial, Am Heart J, vol.200, pp.44-50, 2018. ,
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study, Am Heart J, vol.184, pp.81-88, 2017. ,
Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR, J Am Coll Cardiol Img, 2016. ,
,
, Predisposing Factors, and Clinical Implications, J Am Coll Cardiol, vol.68, pp.2059-69, 2016.
Valve thrombosis following transcatheter aortic valve implantation: a systematic review, Rev Espanola Cardiol Engl Ed, vol.38, issue.36, pp.198-204, 2015. ,
The Fluid Mechanics of Transcatheter Heart Valve Leaflet Thrombosis in the Neosinus, Circulation, vol.136, issue.17, pp.1598-609, 2017. ,
Impact of patient-specific TABLEAU 2''Données'issues'de'la'procédure '' Avec'Thrombose' Sans'Thrombose ,
, Avec'Thrombose' Sans'Thrombose' '' '' (n=54)' (n=113)' p'value' Leucocytes!(G/L)!(n=163)! 7,6!±!2, TABLEAU'3'''Données'biologiques'et'échocardiographiques'en'post'TAVI'immédiat
, Hématocrite!(%)!(=n=158)!, vol.37
, !±!12,4! 57,7!±!10,7! 0,088! PAPs!(mmHg)!(n=79)! 34,6!±!9, vol.9
, Les!données!sont!exprimées!en!moyenne±écartItype!(médianIintervalle!interquartile!pour!les!variables!non!normalement! distribuées)!ou!en!nombre!(%).!!TAVI!=!Transcatheter!aortic!valve!implantation!
,
,
,
,
, TABLEAU'4''Diagnostic'de'la'thrombose
, Les!données!sont!exprimées!en!moyenne±écartItype!(médianIintervalle!interquartile!pour!les!variables!non! normalement!distribuées)!ou!en!nombre!(%).!!!Gradient!VGIAo!=!Gradient!Ventricule!gaucheIAorte!
, TABLEAU'5''Traitement'de'la'thrombose'
, Analyse'univariée'et'multivariée'selon'un'modèle'de'régression'logistique'pour'mettre'en'évidence'des' facteurs'de'risque' '' Analyse'univariée' Analyse'multivariée
52! 3,66!I!19,8! <0.001! 9,96! 3,26!I!30,4! <0,001! Clairance!de!la!créatinine!<60ml/min! 1,50! 0,77!I!2,92! 0 ,
!ratio!sont!exprimés!avec!leur!intervalle!de!confiance!à!95%!et!leur!seuil!de!significativité!p.!IMC!=!Indice!de!masse!corporelle! ,
,
Fraction!d'éjection!du!ventricule!gauche! ,
,
, Analyse'univariée'et'multivariée'selon'un'modèle'de'régression'logistique'pour'mettre'en'évidence'des' facteurs'de'risque'chez'les'patients'sans'traitement'anticoagulant' '' Analyse'univariée' Analyse'multivariée
, 03! IMC!>30kg/m2! 1,90! 0,84!I!4,29! 0,12! 2,96! 1,00I8,78! 0,04! 81! 2,71!I!17,1! <0.001! 10,12! 3,05!I!33,5! <0.001! Clairance!de!la!créatinine!<60ml/min! 1
, , vol.10
!ratio!sont!exprimés!avec!leur!intervalle!de!confiance!à!95%!et!leur!seuil!de!significativité!p.!IMC!=!Indice!de!masse!corporelle! ,
,
Fraction!d'éjection!du!ventricule!gauche! ,
,